Company Profile

Bild 1 Bild 2 Bild 3 Bild 4 Bild 5 Bild 6

ICON GENETICS discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. We have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. We offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants.

ICON GENETICS AG, Munich, Germany has been incorporated in 1999. The Company owned two subsidiaries: ICON GENETICS GmbH, Halle, and ICON GENETICS Inc., NJ, USA. In January 2006, the Company has been acquired by BAYER INNOVATION GmbH, a wholly owned subsidiary of BAYER AG. In January 2007, ICON GENETICS AG has been merged into ICON GENETICS GmbH. In January 2012, ICON has been acquired by NOMAD BIOSCIENCE GmbH, Munich, Germany.

So far, ICON GENETICS has generated over 350 FTE-years of research, filed 44 patent applications and exclusively / non-exclusively in-licensed 11 patents. ICON has published a number of milestone research papers in most important peer-review scientific journals.

ICON has built its own GMP-certified facility. Since 2010, ICON is running phase I clinical trials with its first product – individualized vaccine for non-Hodgkin‘s Lymphoma. ICON has a pipeline of cancer antibodies (including several biobetters) and vaccines.

ICON GENETICS is managed by experienced directors and research managers with extensive knowledge of business and corporate research.

Bild 1 Bild 2 Bild 3 Bild 4 Bild 5 Bild 6 Bild 7

Company Profile

Bild 1 Bild 2 Bild 3 Bild 4 Bild 5 Bild 6

ICON GENETICS discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. We have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. We offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants.

ICON GENETICS AG, Munich, Germany has been incorporated in 1999. The Company owned two subsidiaries: ICON GENETICS GmbH, Halle, and ICON GENETICS Inc., NJ, USA. In January 2006, the Company has been acquired by BAYER INNOVATION GmbH, a wholly owned subsidiary of BAYER AG. In January 2007, ICON GENETICS AG has been merged into ICON GENETICS GmbH. In January 2012, ICON has been acquired by NOMAD BIOSCIENCE GmbH, Munich, Germany.

So far, ICON GENETICS has generated over 350 FTE-years of research, filed 44 patent applications and exclusively / non-exclusively in-licensed 11 patents. ICON has published a number of milestone research papers in most important peer-review scientific journals.

ICON has built its own GMP-certified facility. Since 2010, ICON is running phase I clinical trials with its first product – individualized vaccine for non-Hodgkin‘s Lymphoma. ICON has a pipeline of cancer antibodies (including several biobetters) and vaccines.

ICON GENETICS is managed by experienced directors and research managers with extensive knowledge of business and corporate research.

Bild 1 Bild 2 Bild 3 Bild 5 Bild 6 Bild 7